Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
COMPLETED
NCT01655771
PHASE1
TD-1211 Single-Dose Study in Elderly and Young Healthy Subjects
Sponsor: Glycyx Therapeutics
View on ClinicalTrials.gov
Summary
The purpose of this study is to measure the way in which TD-1211 is absorbed and eliminated by the body and to evaluate whether it is safe and well tolerated.
Official title: A Phase 1, Open-Label, Single-Dose, Parallel-Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of TD-1211 Administered Orally to Elderly and Young Healthy Subjects
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
47
Start Date
2012-08
Completion Date
2013-03
Last Updated
2026-05-22
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
TD-1211 Dose 1
DRUG
TD-1211 Dose 2
Locations (1)
ICON Development Solutions
San Antonio, Texas, United States